📣 VC round data is live. Check it out!

Monte Rosa Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Monte Rosa Therapeutics and similar public comparables like Palvella Therapeutics, Immunocore Holdings, AnaptysBio, Alembic Pharmaceuticals and more.

Monte Rosa Therapeutics Overview

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.


Founded

2019

HQ

United States

Employees

134

Financials (LTM)

Revenue: $90M
EBITDA: ($46M)

EV

$872M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Monte Rosa Therapeutics Financials

Monte Rosa Therapeutics reported last 12-month revenue of $90M and negative EBITDA of ($46M).

In the same LTM period, Monte Rosa Therapeutics generated $90M in gross profit, ($46M) in EBITDA losses, and had net loss of ($93M).

Revenue (LTM)


Monte Rosa Therapeutics P&L

In the most recent fiscal year, Monte Rosa Therapeutics reported revenue of $124M and EBITDA of ($46M).

Monte Rosa Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (37%) and net margin of (31%).

See analyst estimates for Monte Rosa Therapeutics
LTMLast FY202320242025202620272028
Revenue$90M$124M-$76M$124M
Gross Profit$90M---$124M
Gross Margin100%---100%
EBITDA($46M)($46M)($137M)($73M)($46M)
EBITDA Margin(51%)(37%)-(97%)(37%)
EBIT Margin(122%)(44%)-(107%)(44%)
Net Profit($93M)($39M)($135M)($73M)($39M)
Net Margin(103%)(31%)-(96%)(31%)

Financial data powered by Morningstar, Inc.

Monte Rosa Therapeutics Stock Performance

Monte Rosa Therapeutics has current market cap of $1B, and enterprise value of $872M.

Market Cap Evolution


Monte Rosa Therapeutics' stock price is $17.74.

Monte Rosa Therapeutics share price decreased by 10.0% in the last 30 days, and increased by 294.7% in the last year.

Monte Rosa Therapeutics has an EPS (earnings per share) of $-0.46.

See more trading valuation data for Monte Rosa Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$872M$1B-9.9%-10.0%7.8%294.7%$-0.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Monte Rosa Therapeutics Valuation Multiples

Monte Rosa Therapeutics trades at 9.7x EV/Revenue multiple, and (19.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Monte Rosa Therapeutics

EV / Revenue (LTM)


Monte Rosa Therapeutics Financial Valuation Multiples

As of June 3, 2026, Monte Rosa Therapeutics has market cap of $1B and EV of $872M.

Monte Rosa Therapeutics has a P/E ratio of (16.1x).

LTMLast FY202320242025202620272028
EV/Revenue9.7x7.0x-11.5x7.0x
EV/EBITDA(19.0x)(19.0x)(6.4x)(11.9x)(19.0x)
EV/EBIT(7.9x)(16.1x)(6.1x)(10.7x)(16.1x)
EV/Gross Profit9.7x---7.0x
P/E(16.1x)(38.8x)(11.1x)(20.6x)(38.8x)
EV/FCF(38.8x)(31.7x)(13.9x)22.9x(31.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Monte Rosa Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Monte Rosa Therapeutics Margins & Growth Rates

Monte Rosa Therapeutics decreased revenue by 64% and EBITDA by 25% in the last fiscal year.

In the most recent fiscal year, Monte Rosa Therapeutics reported EBITDA margin of (37%) and net margin of (31%).

See estimated margins and future growth rates for Monte Rosa Therapeutics

Monte Rosa Therapeutics Margins

Last FY202420252026202720282029
Gross Margin--100%100%
EBITDA Margin(37%)(97%)(37%)(77%)
EBIT Margin(44%)(107%)(44%)(421%)
Net Margin(31%)(96%)(31%)(376%)
FCF Margin(22%)50%(22%)6%

Monte Rosa Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(64%)-64%(64%)
Gross Profit Growth---(64%)
EBITDA Growth(25%)(47%)(37%)(25%)
EBIT Growth245%(43%)(33%)245%
Net Profit Growth333%(46%)(47%)333%
FCF Growth(110%)(160%)(172%)(110%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Monte Rosa Therapeutics Operational KPIs

Monte Rosa Therapeutics' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $1.3M for the same period.

Monte Rosa Therapeutics' Rule of 40 is (141%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Monte Rosa Therapeutics' Rule of X is (237%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Monte Rosa Therapeutics
LTMLast FY20242025202620272028
Rule of 40(95%)(141%)--
Bessemer Rule of X(162%)(237%)--
Revenue per Employee-$0.9M--
Opex per Employee-$1.3M--
G&A Expenses to Revenue44%29%47%29%
R&D Expenses to Revenue179%114%161%114%
Opex to Revenue-144%207%144%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Monte Rosa Therapeutics Competitors

Monte Rosa Therapeutics competitors include Palvella Therapeutics, Immunocore Holdings, AnaptysBio, Alembic Pharmaceuticals, Amylyx Pharmaceuticals, Vir Biotechnology, Biohaven, Ab&B Bio-Tech, InventisBio and MBX Biosciences.

Most Monte Rosa Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Palvella Therapeutics--(34.5x)(25.5x)
Immunocore Holdings2.7x2.6x(298.4x)(47.1x)
AnaptysBio5.2x6.5x17.6x18.8x
Alembic Pharmaceuticals2.4x2.1x14.5x13.5x
Amylyx Pharmaceuticals--(7.9x)(7.5x)
Vir Biotechnology15.9x10.1x(2.4x)(2.8x)
Biohaven--(2.0x)(2.4x)
Ab&B Bio-Tech41.5x-(59.2x)-

This data is available for Pro users. Sign up to see all Monte Rosa Therapeutics competitors and their valuation data.

Start Free Trial

Monte Rosa Therapeutics VC Funding History

Before going public, Monte Rosa Therapeutics raised $224M in total equity funding, across 3 rounds.


Monte Rosa Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-21Series CAvoro Capital Advisors$95M-Monte Rosa Therapeutics is a biotechnology company developing molecular glue degraders (MGDs), small molecule drugs that utilize the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, targeting undruggable proteins in genomically-defined diseases like cancer. The company announced a $95 million Series C financing on approximately December 3, 2021, led by Avoro Capital Advisors, with participation from new investors including Fidelity Management & Research Company LLC, BlackRock, T. Rowe Price Associates, RTW Investments, and existing investors like Versant Ventures, New Enterprise Associates, Aisling Capital, Cormorant Asset Management, HBM Healthcare Investments, GV, Amzak Health, Sixty Degree Capital, Casdin Capital, and Cambridge Asset Management. The proceeds were intended to accelerate the next-generation protein degradation platform, initiate IND-enabling studies on lead candidate MRT-2359 targeting GSPT1 for MYC-driven tumors later that year, and advance additional programs into lead optimization. Monte Rosa's platform integrates proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection, and computational chemistry to predict protein degradation profiles. At the time, the company was preparing to expand its pipeline across multiple therapeutic indications. The company went public in June 2021 via an IPO offering 11,700,000 shares of common stock.
Sep-20Series BAisling Capital; Amzak Health Investors; Cambridge Asset Management; Casdin Capital; Cormorant Asset Management; GV; HBM Healthcare Investments; HBM Partners; New Enterprise Associates; Sixty Degree Capital; Versant Ventures$96M-Monte Rosa Therapeutics, a biotechnology company developing precision medicines using small molecule degraders (molecular glues) to target undruggable disease-causing proteins, closed a $96 million Series B financing on September 24, 2020. The round was led by Aisling Capital, with participation from founding investor Versant Ventures, existing investor New Enterprise Associates, and new investors including HBM Healthcare Investments, HBM Partners, Cormorant Asset Management, GV, Amzak Health Investors, Casdin Capital, Sixty Degree Capital, and Cambridge Asset Management. The proceeds were intended to accelerate pipeline growth, advance development candidates into clinical trials, and enhance the company's protein degradation platform, which integrates proteomics, structural biology, and small-molecule design to hijack the body's ubiquitin ligase system for degrading proteins implicated in genomically defined diseases like cancer. Monte Rosa originated as a spinout from Versant Ventures' Ridgeline Discovery Engine in Basel, Switzerland, in collaboration with The Institute of Cancer Research (ICR) in London and Cancer Research UK. Academic co-founders include Professor Ian Collins and Dr. Rajesh Chopra, with ongoing collaborations. The company had previously raised a $32.5 million Series A in May 2020 led by Versant. In connection with the Series B, Andrew Schiff from Aisling Capital and Chandra P. Leo from HBM Partners joined the board.
May-20Series ANew Enterprise Associates; Versant Ventures$33M-Monte Rosa Therapeutics is a Boston-based biotechnology company developing novel molecular glue degrader (MGD) medicines for oncology, autoimmune, and inflammatory diseases. The company employs a proprietary QuEEN platform that combines protein degradation libraries with proteomics, structural biology, AI/machine learning, and computational chemistry to identify targets and design selective degraders. Lead programs include MRT-2359 (Phase 1/2 in MYC-driven tumors), MRT-6160, and MRT-8102, all in early clinical development. Monte Rosa has secured substantial non-dilutive funding through major pharma partnerships: Novartis provided $150 million upfront plus up to $2.1 billion in milestones for MRT-6160, plus $120 million upfront with up to $5.4 billion in milestones for immunology and inflammation programs; Roche provided $50 million upfront with potential milestone payments exceeding $2 billion. In fiscal 2024, the company recorded revenue of $75.62 million, with trailing twelve-month revenue reaching approximately $177.99 million as of mid-2025, representing substantial growth from its pre-revenue stage. However, the company historically incurred significant operating losses since inception and anticipates continued losses as it advances its early-stage pipeline through clinical development, requiring substantial additional capital deployment.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Monte Rosa Therapeutics

When was Monte Rosa Therapeutics founded?Monte Rosa Therapeutics was founded in 2019.
Where is Monte Rosa Therapeutics headquartered?Monte Rosa Therapeutics is headquartered in United States.
How many employees does Monte Rosa Therapeutics have?As of today, Monte Rosa Therapeutics has over 134 employees.
Who is the CEO of Monte Rosa Therapeutics?Monte Rosa Therapeutics' CEO is Markus Warmuth.
Is Monte Rosa Therapeutics publicly listed?Yes, Monte Rosa Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Monte Rosa Therapeutics?Monte Rosa Therapeutics trades under GLUE ticker.
When did Monte Rosa Therapeutics go public?Monte Rosa Therapeutics went public in 2021.
Who are competitors of Monte Rosa Therapeutics?Monte Rosa Therapeutics main competitors include Palvella Therapeutics, Immunocore Holdings, AnaptysBio, Alembic Pharmaceuticals, Amylyx Pharmaceuticals, Vir Biotechnology, Biohaven, Ab&B Bio-Tech, InventisBio, MBX Biosciences.
What is the current market cap of Monte Rosa Therapeutics?Monte Rosa Therapeutics' current market cap is $1B.
What is the current revenue of Monte Rosa Therapeutics?Monte Rosa Therapeutics' last 12 months revenue is $90M.
What is the current revenue growth of Monte Rosa Therapeutics?Monte Rosa Therapeutics revenue growth (NTM/LTM) is (44%).
What is the current EV/Revenue multiple of Monte Rosa Therapeutics?Current revenue multiple of Monte Rosa Therapeutics is 9.7x.
Is Monte Rosa Therapeutics profitable?No, Monte Rosa Therapeutics is not profitable.
What is the current EBITDA of Monte Rosa Therapeutics?Monte Rosa Therapeutics has negative EBITDA and is not profitable.
What is Monte Rosa Therapeutics' EBITDA margin?Monte Rosa Therapeutics' last 12 months EBITDA margin is (51%).
What is the current EV/EBITDA multiple of Monte Rosa Therapeutics?Current EBITDA multiple of Monte Rosa Therapeutics is (19.0x).
What is the current FCF of Monte Rosa Therapeutics?Monte Rosa Therapeutics' last 12 months FCF is ($22M).
What is Monte Rosa Therapeutics' FCF margin?Monte Rosa Therapeutics' last 12 months FCF margin is (25%).
What is the current EV/FCF multiple of Monte Rosa Therapeutics?Current FCF multiple of Monte Rosa Therapeutics is (38.8x).
How many companies Monte Rosa Therapeutics has acquired to date?Monte Rosa Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Monte Rosa Therapeutics has invested to date?Monte Rosa Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Monte Rosa Therapeutics

Lists including Monte Rosa Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial